Study of Samalizumab in Patients With Advanced Cancer

Study Identifier:
ALXN6000-ONC-102
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Cancer - Other
Study Drug
  • Drug: Samalizumab
Date
Nov 2016 - Sep 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Cancer - Other
Study Drug
  • Drug: Samalizumab
Date
Nov 2016 - Sep 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

This is a multicenter, open-label, dose-escalation, Phase 1 study of intravenous (IV) samalizumab to determine its maximum tolerated dose (MTD), overall safety/tolerability, pharmacokinetic and pharmacodynamic parameters, and efficacy in participants with advanced cancer. The study was terminated for administrative reasons and not due to any safety concerns.

Trial Locations

Location
Status
Location
New Haven, Connecticut, United States, 06510
Status
N/A
Location
Grand Rapids, Michigan, United States, 49503
Status
N/A
Location
San Antonio, Texas, United States, 78229
Status
N/A